Literature DB >> 20858716

PALB2/FANCN: recombining cancer and Fanconi anemia.

Marc Tischkowitz1, Bing Xia.   

Abstract

Partner and localizer of BRCA2 (PALB2) was originally identified as a BRCA2-interacting protein that is crucial for key BRCA2 genome caretaker functions. It subsequently became clear that PALB2 was another Fanconi anemia (FA) gene (FANCN), and that monoallelic PALB2 mutations are associated with increased risk of breast and pancreatic cancer. Mutations in PALB2 have been identified in breast cancer families worldwide, and recent studies have shown that PALB2 also interacts with BRCA1. Here, we summarize the molecular functions and clinical phenotypes of this key DNA repair pathway component and discuss how its discovery has advanced our knowledge of both FA and adult cancer predisposition.
© 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858716      PMCID: PMC2948578          DOI: 10.1158/0008-5472.CAN-10-1012

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

2.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

3.  Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.

Authors:  Blanche P Alter; Philip S Rosenberg; Lawrence C Brody
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

4.  BRCA1 induces antioxidant gene expression and resistance to oxidative stress.

Authors:  Insoo Bae; Saijun Fan; Qinghui Meng; Jeong Keun Rih; Hee Jong Kim; Hyo Jin Kang; Jingwen Xu; Itzhak D Goldberg; Anil K Jaiswal; Eliot M Rosen
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  PALB2 mutations in European familial pancreatic cancer families.

Authors:  E P Slater; P Langer; E Niemczyk; K Strauch; J Butler; N Habbe; J P Neoptolemos; W Greenhalf; D K Bartsch
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

6.  A recurrent mutation in PALB2 in Finnish cancer families.

Authors:  Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist
Journal:  Nature       Date:  2007-02-07       Impact factor: 49.962

7.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

8.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

9.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.

Authors:  Sarah Reid; Detlev Schindler; Helmut Hanenberg; Karen Barker; Sandra Hanks; Reinhard Kalb; Kornelia Neveling; Patrick Kelly; Sheila Seal; Marcel Freund; Melanie Wurm; Sat Dev Batish; Francis P Lach; Sevgi Yetgin; Heidemarie Neitzel; Hany Ariffin; Marc Tischkowitz; Christopher G Mathew; Arleen D Auerbach; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  83 in total

1.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

2.  ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair.

Authors:  Jean-Yves Bleuyard; Rémi Buisson; Jean-Yves Masson; Fumiko Esashi
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

3.  Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.

Authors:  Irene Catucci; Roni Milgrom; Anya Kushnir; Yael Laitman; Shani Paluch-Shimon; Sara Volorio; Filomena Ficarazzi; Loris Bernard; Paolo Radice; Eitan Friedman; Paolo Peterlongo
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 4.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

5.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.

Authors:  Silvia Casadei; Barbara M Norquist; Tom Walsh; Sunday Stray; Jessica B Mandell; Ming K Lee; John A Stamatoyannopoulos; Mary-Claire King
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

6.  Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.

Authors:  Yanying Huo; Hong Cai; Irina Teplova; Christian Bowman-Colin; Guanghua Chen; Sandy Price; Nicola Barnard; Shridar Ganesan; Vassiliki Karantza; Eileen White; Bing Xia
Journal:  Cancer Discov       Date:  2013-05-06       Impact factor: 39.397

7.  Partner and Localizer of BRCA-2 (PALB-2) Mutation Analysis Is Rapidly Being Adopted into Clinical Practice.

Authors:  Serap Erel; Darcy L Thull; Atilla Soran
Journal:  J Breast Health       Date:  2014-10-01

Review 8.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

9.  Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Authors:  G Cecener; G Guney Eskiler; U Egeli; B Tunca; A Alemdar; S Gokgoz; I Tasdelen
Journal:  Mol Biol Rep       Date:  2016-08-29       Impact factor: 2.316

10.  PALB2 mutations and breast-cancer risk.

Authors:  Michele K Evans; Dan L Longo
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.